Technology | Breast Imaging | October 02, 2015

Hologic Highlighting Breast Tomosynthesis at RSNA 2015

Product offerings will focus on 3-D mammography, breast biopsy systems

Hologic, RSNA 2015, breast tomosynthesis, breast biopsy systems

I-View contrast enhanced 2-D mammography image courtesy of Hologic

October 2, 2015 — At the Radiological Society of North America’s (RSNA) 2015 annual meeting, Hologic will emphasize its breast tomosynthesis offerings across multiple product lines.

The company expects to see continued interest in the field, as a recent survey of U.S. mammography providers by KLAS Research found 65 percent of respondents planned to invest in breast tomosynthesis technology during the next two years, up from 57 percent in 2014.

Hologic’s featured products will include:  

Genius 3D Mammography exams

Available on Hologic’s Selenia Dimensions system, Genius 3D Mammography exams help find breast cancers earlier, while reducing recall rates and false positives.

C-View-generated 2-D images from a Selenia Dimensions breast tomosynthesis dataset

The C-View software is designed to generate 2-D images from Genius 3D Mammography image slices, eliminating the need for a separate 2-D exposure during a 3-D exam. C-View technology is designed to offer radiologists and patients a number of benefits including a reduction in X-ray exposures leading to shorter exam times (less than 4 second scan per view), and increased patient comfort from the shorter compression time.

Affirm Breast Biopsy Guidance System for Selenia Dimensions

The Affirm 3-D breast biopsy technology is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions found with the Genius 3D Mammography exam. The Affirm system is designed to accelerate and simplify the biopsy workflow compared with previous stereotactic biopsy procedures.

I-View contrast enhanced 2-D mammography and tomosynthesis fusion

Using an iodinated contrast agent, I-View software on the Selenia Dimensions system enables users to image the functional 2-D contrast uptake and the morphological Genius 3D Mammography image in rapid sequence and combine these two image sets into a single fused study. In the fused study, the 2-D contrast image can identify potential lesions based on their physiological state due to an increase in the contrast agent uptake. The 3-D image can then be overlaid on the 2-D contrast image and provide morphological information on the lesion, such as improved visibility of associated spiculations.

I-View dual modality contrast-enhanced imaging is designed to confirm findings and localize lesions when breast cancer imaging results are inconclusive. A contrast enhanced exam using the software can be performed in less than 10 minutes, in the same exam room and on the same screening equipment.

The I-View imaging mode is designed to offer several advantages over conventional contrast breast magnetic resonance imaging (MRI):

  • Reduced cost;
  • Contrast imaging availability to patients for whom MRI is contraindicated; and
  • Access to patients in areas where MRI systems are not available.

I-View imaging software is an extension of the existing indication for diagnostic imaging with the Selenia Dimensions system. The product is U.S. Food and Drug Administration (FDA) 510(k) cleared and CE marked.

Quantra breast density assessment software for breast tomosynthesis

Quantra v2.1 software is FDA-cleared and compatible for breast tomosynthesis. It features the latest advances in density assessment algorithms, a newly designed and easy to read Secondary Capture display using BI-RADS 5th edition terminology, and user-friendly naming for all Quantra assessed values.

In addition to their tomosynthesis offerings, Hologic will also display other products including:

Sertera biopsy device, the newest member of Hologic’s ultrasound-guided breast biopsy family. The device is a disposable, core needle biopsy device available in multiple gauge sizes; it is lightweight and designed to be completely armed and fired with one hand.

Brevera breast biopsy system with CorLumina imaging technology. An advanced biopsy platform designed to increase clinical confidence and reduce procedure times.

New prone biopsy system. The system is a fully redesigned dedicated prone biopsy solution. The prone table uses the latest mammography imaging technology including 3-D imaging. It is designed to make it fast and easy to identify and confidently target lesions, especially those found using the Genius 3D Mammography exam.

For more information: www.hologic.com

Related Content

LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Agfa Brings Intelligent Radiography to RSNA 2018
News | Digital Radiography (DR) | September 17, 2018
September 17, 2018 — At the 2018 Radiological Society of North America (RSNA) annual meeting, Nov.
Siemens Healthineers Announces First U.S. Install of Somatom go.Top CT
News | Computed Tomography (CT) | September 17, 2018
September 17, 2018 — The Ohio State University Wexner Medical Center in Columbus recently became the first healthcare
SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

News | Digital Radiography (DR) | September 13, 2018
At RSNA 2018, radiology professionals will discover intelligent
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Overlay Init